Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS ‐986231) in Chronic Heart Failure: A Randomized Trial

ConclusionIn patients with chronic HFrEF, the hemodynamic effects of cimlanod and NTG are similar. The effects of cimlanod may be explained by venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing trials of cimlanod will further define its potential role in the treatment of heart failure.

Source: European Journal of Heart Failure - February 23, 2021 Category: Cardiology Authors: Ninian N. Lang, Faheem A. Ahmad, John G. Cleland, Christopher M. O'Connor, John R. Teerlink, Adriaan A. Voors, Jorg Taubel, Anke R. Hodes, Mohamed Anwar, Ravi Karra, Yasushi Sakata, Shiro Ishihara, Roxy Senior, Abhishek Khemka, Narayana G. P Tags: Research Article Source Type: research